Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ8EAJ)

• Drug Name: BI 894416 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMJ8EAJ

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine-protein kinase SYK (SYK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fostamatinib	DM6AUHV	Immune thrombocytopenic purpura	3B64.13	Approved	[3]
Fostamatinib disodium	DM3274D	Thrombocytopenia	3B64	Phase 3	[4]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[5]
TAK-659	DMJH3U0	Diffuse large B-cell lymphoma	2A81	Phase 2	[6]
GS-9876	DM9Q2B6	Cutaneous lupus erythematosus	EB5Z	Phase 2	[7]
GS-9973	DMKWCTR	Acute myeloid leukaemia	2A60	Phase 2	[8]
Cevidoplenib	DM9QU5G	Rheumatoid arthritis	FA20	Phase 2	[9]
HM43239	DMV1SDA	Acute myeloid leukaemia	2A60	Phase 1/2	[10]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[11]
SKI-O-703	DMTSKXR	Rheumatoid arthritis	FA20	Phase 1	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase SYK (SYK)	TTOU65C	KSYK_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03971539) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 894416 Versus Placebo in Male Patients With Asthma (Single-blind, Randomised, Placebo-controlled, Parallel Group Design). U.S.National Institutes of Health.
• [2] Synthesis of BI 894416 and BI 1342561, two potent and selective spleen tyrosine kinase inhibitors, labeled with carbon 14 and with deuterium. J Labelled Comp Radiopharm. 2023 Apr-May;66(4-6):155-168.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Company report (Portola Pharmaceuticals)
• [6] J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
• [9] A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2023 Mar 8;211(1):31-45.
• [10] Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
• [11] The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.